```
**huntington* chorea; *n
                            triatum
  ?ds
  Set
          Items
                  Description
  S1
           8982
                  (NEUROGENESIS) OR (NEURONAL (W) PRODUCTION)
  S2
                  S1 AND ((NEUROTROPHIC (W) FACTOR) OR (BDNF) OR (NEUROTROPH-
            354
               IN??))
  S3
              7
                  S2 AND (VECTOR OR (GENE (W) THERAPY))
  S4
                  RD (unique items)
              6
  S5
              7
                 S2 AND (VECTOR)
  S6
             40 S2 AND (TREATMENT OR THERAPY)
  S7
             0 S6 AND (NEURODEGENERATIVE (W) CONDITION)
  S8
              0 S6 AND (HUNTINGTON'S (W) DISEASE)
  S9
              2 S6 AND (HUNTINGTON)
  S10
              2
                 RD (unique items)
  S11
             27
                 RD S6 (unique items)
  S12
             4
                  S11 AND REVIEW
  S13
             28
                  S2 AND REVIEW
  S14
             24
                  RD (unique items)
  S15
             1
                  S14 AND (HUNTINGTON)
                  (NEURODEGENERATIVE (W) DISEASE) AND (NEUROTROPHIC (W) FACT-
  S16
            167
              OR)
 S17
                  S16 AND (HUNTINGTON)
             11
 S18
                 S17 AND (BDNF)
 ?s s16 and ((lateral (w) ventricles) or (ventricular (w) zone))
               167 S16
           293381 LATERAL
            44430 VENTRICLES
             5365 LATERAL (W) VENTRICLES
           443023 VENTRICULAR
           178549 ZONE
             2073 VENTRICULAR (W) ZONE
      S19
                0 S16 AND ((LATERAL (W) VENTRICLES) OR (VENTRICULAR (W)
                   ZONE))
 ?s s16 and (treatment or therapy)
              167 S16
          3813291 TREATMENT
          4408917 THERAPY
      S20
              105 S16 AND (TREATMENT OR THERAPY)
 ?s s20 and review
              105 S20
          1243606 REVIEW
              18 S20 AND REVIEW
      S21
 ?rd
 ... completed examining records
               14 RD (unique items)
 ?s s22 and (BDNF)
              14 S22
             7897 BDNF
               2 S22 AND (BDNF)
?rd
...completed examining records
     S24
               2 RD (unique items)
?t s24/3, k/all
 24/3,K/1
              (Item 1 from file: 73)
DIALOG(R) File 73: EMBASE
(c) 2002 Elsevier Science B.V. All rts. reserv.
07298854
             EMBASE No: 1998197299
  The relationship among the neurotrophins, Parkinson's disease,
Alzheimer's disease and schizophrenia
 LA RELACION ENTRE LAS NEUROTROFINAS Y LAS ENFERMEDADES DE PARKINSON,
ALZHEIMER Y ESQUIZOFRENIA
 Rodriguez J.C.G.; Oviedo H.H.; Gonzalez J.C.P.
 J.C.G. Rodriguez, Avenida 17.5008 e/ 50 y 52, Playa, Ciudad de La Habana
```

09161999 97071950 PMID: 8914795

Advances in the development of herpes simplex virus-based gene transfer vectors for the nervous system.

Fink D J; Ramakrishnan R; Marconi P; Goins W F; Holland T C; Glorioso J C Department of Molecular Genetics and Biochemistry, University of Pittsburgh School of Medicine, PA, USA.

Clinical neuroscience (New York, N.Y.) (UNITED STATES) 3 (5) p284-91, ISSN 1065-6766 Journal Code: 9315128

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM Record type: Completed

Herpes simplex virus (HSV) is an attractive candidate vector for *treatment* of nervous system disease by *gene* *therapy*. Here we *review* molecular aspects of the natural biology of HSV as it relates to vector design and application. Although gene transfer and transient expression was readily achieved using first generation replication defective HSV vectors, these vectors did not provide for long-term transgene expression, a prerequisite for effective *treatment* of *neurodegenerative* *disease*. The principle impediments to effective use of HSV vectors are residual toxicity of non-replicating vectors and the silencing of transgene expression from persisting latent...

Descriptors: *Gene* *Therapy*; *Gene Transfer Techniques; *Genetic Vectors; *Nervous System Diseases--*therapy*--TH; *Simplexvirus--genetics--GE?

```
Set
        Items
                Description
s1
           0
                (HUNTINGTON'S (W) DISEASE) AND (THERAPY OR TREATMENT)
S2
                (NEURODEGENERATIVE (W) DISEASE) AND (TREATMENT OR THERAPY)
          281
S3
               S2 AND REVIEW
           35
S4
            3
               S3 AND (HUNTINGTON)
S5
                S3 AND (NEUROTROPHIC (W) FACTOR)
S6
         2567
                (NEURONAL (W) (RECRUITMENT OR PRODUCTION)) OR (NEUROGENESI-
            S)
s7
           71
               S6 AND (NEUROTROPHIC (W) FACTOR)
S8
           47
               S6 AND (NEUROTROPHIN)
S9
               S7 AND ((LATERAL (W) VENTRICLES) OR (VENTRICULAR (W) WALL))
           2
S10
               S8 AND ((LATERAL (W) VENTRICLES) OR (VENTRICULAR (W) WALL))
           0
S11
               S7 AND (INTRAVENTRICULAR)
           4
S12
               S7 AND (HUNTINGTON)
           1
S13
           0
               S3 AND (BDNF)
S14
           1
               S3 AND (NEUROTROPHIN)
S15
           5
                S3 AND (GENE (W) THERAPY)
?logoff
       07jun02 16:51:02 User259876 Session D355.2
                    2.552 DialUnits File155
               $3.78 18 Type(s) in Format 3
           $3.78 18 Types
   $11.95 Estimated cost File155
    $4.33 TELNET
   $16.28 Estimated cost this search
   $16.61 Estimated total session cost
                                          2.645 DialUnits
```

Status: Signed Off. (20 minutes)